Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Sharon, Mates"'
Autor:
Trisha Suppes, Suresh Durgam, Susan G. Kozauer, Richard Chen, Hassan D. Lakkis, Robert E. Davis, Andrew Satlin, Kimberly E. Vanover, Sharon Mates, Roger S. McIntyre, Mauricio Tohen
Publikováno v:
Bipolar Disorders.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::782c8b69f8de58be03b94a3fd3503c74
https://doi.org/10.1111/bdi.13310
https://doi.org/10.1111/bdi.13310
Publikováno v:
CNS Spectrums. 28:233-233
IntroductionApproved therapeutics for bipolar depression are associated with a range of undesirable side effects. Lumateperone (LUMA), a mechanistically novel antipsychotic that simultaneously modulates serotonin, dopamine, and glutamate neurotransmi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d00558c680c1c0d35c73487d37db0a09
https://doi.org/10.1017/s1092852923001591
https://doi.org/10.1017/s1092852923001591
Autor:
Kimberly E. Vanover, Joseph R. Calabrese, Robert E. Davis, Andrew Satlin, Gary S. Sachs, Richard Chen, Suresh Durgam, Susan Kozauer, Sharon Mates
Publikováno v:
The American journal of psychiatry. 178(12)
In a phase 3 randomized double-blind placebo-controlled study, the authors investigated the efficacy and safety of 42 mg/day of lumateperone in patients with bipolar I or bipolar II disorder experiencing a major depressive episode.Patients 18-75 year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0521b15b4dda1f43674dd26afab85f3b
https://pubmed.ncbi.nlm.nih.gov/36048493
https://pubmed.ncbi.nlm.nih.gov/36048493
Autor:
Kimberly E. Vanover, Sharon Mates, John M. Kane, Andrew Satlin, Richard Chen, Robert C. Davis, Suresh Durgam
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
Lumateperone, an antipsychotic that is US Food and Drug Administration-approved for the treatment of schizophrenia, has a novel mechanism of action that may confer beneficial effects with im
Lumateperone, an antipsychotic that is US Food and Drug Administration-approved for the treatment of schizophrenia, has a novel mechanism of action that may confer beneficial effects with im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::808100a3fdcc4714e07c02ea5c7f8ad5
https://pubmed.ncbi.nlm.nih.gov/34054112
https://pubmed.ncbi.nlm.nih.gov/34054112
A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia
Autor:
Gretchen L, Snyder, Kimberly E, Vanover, Robert E, Davis, Peng, Li, Allen, Fienberg, Sharon, Mates
Publikováno v:
Advances in pharmacology (San Diego, Calif.). 90
Schizophrenia is associated with a tremendous individual and societal burden. The disease is characterized by a complex set of symptoms including psychosis, hallucinations, delusions and related positive symptoms combined with social function deficit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::daa9d7848341c45ad2b7fd0e22446796
https://pubmed.ncbi.nlm.nih.gov/33706936
https://pubmed.ncbi.nlm.nih.gov/33706936
A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia
Autor:
Gretchen L. Snyder, Peng Li, Robert E. Davis, Sharon Mates, Kimberly E. Vanover, Allen A. Fienberg
Publikováno v:
A Tribute to Paul Greengard (1925-2019) ISBN: 9780128225165
Schizophrenia is associated with a tremendous individual and societal burden. The disease is characterized by a complex set of symptoms including psychosis, hallucinations, delusions and related positive symptoms combined with social function deficit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ac6e5c1ac264ecc9af1a992429900e0
https://doi.org/10.1016/bs.apha.2020.09.001
https://doi.org/10.1016/bs.apha.2020.09.001
Autor:
Robert E. Davis, Kimberly E. Vanover, Sharon Mates, Christoph U. Correll, Andrew Satlin, Richard Chen
Publikováno v:
Schizophrenia research. 228
Lumateperone is a mechanistically novel agent FDA-approved for the treatment of schizophrenia. Efficacy and favorable tolerability of lumateperone were demonstrated in 2 short-term placebo-controlled studies in patients with schizophrenia. This open-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ce02497cb856a7eb19ae551ee346d86
https://pubmed.ncbi.nlm.nih.gov/33453691
https://pubmed.ncbi.nlm.nih.gov/33453691
Autor:
Robert E. Litman, Kimberly E. Vanover, Dean F. Wong, Lorena Gapasin, Robert E. Davis, Michal Weingart, Yun Zhou, Weiguo Ye, Jelena Saillard, James Robert Brašić, Sharon Mates
Publikováno v:
Neuropsychopharmacology
Dopamine D2 receptor occupancy (D2RO) is a key feature of all currently approved antipsychotic medications. However, antipsychotic efficacy associated with high D2RO is often limited by side effects such as motor disturbances and hyperprolactinemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d60c0bbdc6d974641c29c5e67a443f33
http://europepmc.org/articles/PMC6333832
http://europepmc.org/articles/PMC6333832
Autor:
Andrew Satlin, Sharon Mates, Robert C. Davis, Christoph U. Correll, William Rowe, Suresh Durgam, Kimberly E. Vanover
Publikováno v:
CNS Spectrums. 25:317-318
Introduction:Lumateperone (lumateperone tosylate, ITI-007) is an investigational drug for the treatment of schizophrenia, bipolar depression, and other disorders. Lumateperone has a unique mechanism of action that simultaneously modulates serotonin,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c7d43928f2a984cb9a73ab34521f491
https://doi.org/10.1017/s1092852920001017
https://doi.org/10.1017/s1092852920001017
Autor:
William Rowe, Sharon Mates, John M. Kane, Suresh Durgam, Robert C. Davis, Andrew Satlin, Kimberly E. Vanover, Carol A. Tamminga
Publikováno v:
CNS Spectrums. 25:316-317
Introduction:Lumateperone (ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that modulates serotonin, dopamine, and glutamate neurotransmission. This pooled analysis of lumateperone in 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a264d0c487f3be421a94119994869639
https://doi.org/10.1017/s1092852920001005
https://doi.org/10.1017/s1092852920001005